<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Biochemistry</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7B37377E-AAF0-4C32-BA3D-0395632DCBB7"><gtr:id>7B37377E-AAF0-4C32-BA3D-0395632DCBB7</gtr:id><gtr:firstName>Julian</gtr:firstName><gtr:otherNames>Leether</gtr:otherNames><gtr:surname>Griffin</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FP011705%2F1"><gtr:id>A3F926D6-C2EB-49B8-BC20-218BFD6440AA</gtr:id><gtr:title>Macronutrients and Metabolic Health - Understanding how metabolic disease arises at the population level using metabolomics and lipidomics.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/P011705/1</gtr:grantReference><gtr:abstractText>Both obesity and type 2 diabetes (T2DM) are increasing in the UK, placing significant pressure on the National Health Service and impacting on the health of the UK. We know that some of the major causes of these increases are associated with increased dietary consumption of fats and sugars, as well as a general decrease in physical activity. While current public health advice is to exercise more and eat less calorie dense foods, this health advice has been unable to halt the increases in either obesity or T2DM. While there are a number of drugs used to treat T2DM and the increased fat concentrations found in the blood of individuals with obesity, many have side effects which complicate their long term use and are costly to administer. One central question to the field of diabetes research is why on an individual basis certain people are predisposed to developing insulin resistance (a pre-diabetic state) and subsequent T2DM while others stay metabolically healthy. Addressing this question could help treat those at risk of progression and have a significant impact on the costs of treating this disease and its complications.

In order to do this we use analytical chemistry techniques, including mass spectrometry and Nuclear Magnetic Resonance (NMR) spectroscopy, to measure the total small molecule complement of tissues, cells and biofluids to develop a fingerprint of those metabolites that are associated with disease using a combination of multivariate statistics and pattern recognition techniques. This approach is termed metabolomics. By modelling changes in these metabolites as disease progresses we build up an 'atlas' of response in terms of the key metabolic perturbations associated with the disease. In particular this approach allows us to look at how food intake influences the metabolism of the body, and we can model these changes to look at diet-genotype interactions induced by over-nutrition (eating too much food).

To achieve this aim we have identified four themes to be developed in parallel.

1. Fat cells in health and disease: It is well established that fat cells (referred to as white adipose tissue) have numerous important roles in maintaining healthy metabolism in addition to their role as a major site for storage of fats, including roles in regulating hormones, maintaining body temperature and even contributing to the body clock. We will apply metabolomics in conjunction with molecular biology tools to investigate the balance between lipid storage and how we might influence fat metabolism to reduce obesity. 

2. Ectopic fat deposition: Once the capability of white adipose tissue to store fat has been exceeded, fat deposition occurs inappropriately (ectopically) in other tissues. While the consequences of raised blood glucose are biochemically well defined, we do not understand what the consequences of raised fat concentrations are. We will use comprehensive metabolomic approaches to profile the impact of excessive fat storage in the liver, heart and skeletal muscle, and in particular focus on the progression of fatty liver disease. 

3. Lipidomics at the epidemiology scale: While most animal models are caused by rare errors in single genes which cause T2DM, the most common forms found in patients with diabetes are caused by many genes with a strong environmental interaction, particularly as the result of over nutrition and increased sedentary lifestyles. In order to investigate IR and T2DM development in humans we have developed assays that can be performed on a global scale to allow us to address questions about T2DM and diet, ethnicity and age in epidemiology studies.

4. Method development in mass spectrometry and bioinformatics: To be able to conduct these studies we require being at the forefront of developments in both mass spectrometry and mathematical tools for processing the data. We are currently developing tools in mass spectrometry imagining and ion mobility for lipidomics.</gtr:abstractText><gtr:technicalSummary>Both obesity and type 2 diabetes (T2DM) are increasing in the UK impacting on the nation's health. We aim to address this major health issue by understanding the interactions between over nutrition, subsequent obesity, and the development of insulin resistance (IR), and how this ultimately leads to T2DM and cardiovascular disease. Our global aim is to understand the underlying mechanisms that determine why on an individual basis certain people are predisposed to developing IR and subsequently T2DM, while others stay metabolically healthy. To achieve this aim we have identified four themes to be developed in parallel.
1. White adipose tissue (WAT) function in health and disease: We will apply metabolomics in conjunction with molecular biology tools to investigate the balance between lipid storage and oxidation, and in particular continue our study of the browning of WAT. Furthermore, using measurements of lipid mediators we will investigate further how over nutrition produces adipose tissue dysfunction and inflammation. 
2. Ectopic fat deposition: We will use comprehensive metabolomic and lipidomic mass spectrometry approaches to profile the impact of excessive fat storage in the liver, heart and skeletal muscle, and in particular focus on the transition of non-alcoholic fatty liver disease to non-alcoholic steatohepatitis and cirrhosis, the development of ER-stress in skeletal muscle, and how diet influences cell membrane composition and ultimately cellular function across the body. 
3. Lipidomics at the epidemiology scale: To investigate IR and T2DM development in humans we have developed assays that can be performed on a global scale to allow us to address questions about T2DM and diet, ethnicity and age. These will be applied to large scale studies (n&amp;gt;5000) such as Fenland, PROMIS and INTERVAL.
4. Method development in mass spectrometry and bioinformatics: We are currently developing tools in mass spectrometry imaging and ion mobility for lipidomics.</gtr:technicalSummary><gtr:potentialImpactText>Both obesity and T2DM are increasing in the UK, placing significant pressure on the NHS and impacting on the health of the UK. We aim to address these major health issues by understanding the interactions between over nutrition, subsequent obesity, the development of insulin resistance (IR) and ultimately type 2 diabetes (T2DM), as well as cardiovascular disease (CVD). Central issues for understanding the increase in obesity are the mechanisms that regulate the set point for energy balance and where macronutrients are stored, and we have been at the forefront in developing tools to measure these factors. 

Our work also addresses one of the key priorities identified by the MRC Strategic Review of Nutrition and Energy Balance 2008, which outlined the need for &amp;quot;integrating nutrition and modern biological processes&amp;quot;, and specifically metabolomics, into nutrition research. The work also addresses strategic aim one (research priority theme two: living a long and healthy life) of the MRC Strategic Plan 2014-2019, and in particular 'molecular datasets and disease', 'life course perspective' and 'environment and health.' Furthermore, there is an urgent need to provide skills training in these specialist tools for the next generation of nutritional scientists. By providing scientific leadership in metabolomics, lipidomics and stable isotope technology our group has been integral to &amp;quot;the identified centre of excellence for integrative nutrition research in Cambridge.&amp;quot; This aspect will also help address the national skill shortage of basic and clinical nutrition researchers. This addresses Strategic Aim Four: Supporting Scientists: Sustaining a robust and flourishing environment for world-class medical research. Our research has great relevance to industrial research and development as demonstrated by the fact that Griffin has industrial funding from Selcia, Unilever, Medimmune, AstraZeneca, Waters Corporation, Agilent, Philips, Syngenta and GSK in T2DM and metabolomics. We are involved in initiatives to turn big data into knowledge, contributing to the MRC's drive to increase the use of big data in understanding complex medical problems.

While we will exploit Knowledge Transfer Exchange (KTE) at all levels we expect to continue to specialise in the two areas we have exploited in the current programme. We will collaborate with industry, the university and MRCT to exploit, and where appropriate commercialise our intellectual property. In addition we will continue our projects focussed on dissemination of knowledge and data to key stakeholders including policy-makers, media and public in addition to scientific audiences. One area to raise is that Griffin currently sits on the SACN working group on saturated fats for Public Health England. 

We in the process of exploiting a number of our results with industry as well as using our expertise to assist policy decisions and educate other members of the scientific community and the public. Some of the highlights of this KTE are below:

1. In conjunction with a local company Koulman has developed a novel device to be fitted on the front end of mass spectrometers to enable the analysis of the composition of lipoproteins by LC-MS following size exclusion chromatography. To maximise the potential impact of this work we and MRCT collaborated with a SME through the development process to ensure its applicability to commercial and diagnostic needs. 
2. We have been at the forefront of developing open standards for reporting metabolomics and lipidomic data. We have both contributed to and organised workshops and conferences, as well as authoring a number of leading publications in this area. This has culminated in the development of a world-wide repository for metabolomics data which is is housed at the European Bioinformatics Institute.</gtr:potentialImpactText><gtr:fund><gtr:end>2020-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2089805</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with UCB Pharma</gtr:description><gtr:id>5BF9FCEC-D7A1-4A86-8350-AFD31549113A</gtr:id><gtr:impact>Financial</gtr:impact><gtr:partnerContribution>Financial</gtr:partnerContribution><gtr:piContribution>We have profiled the metabolic outcome of a number of antibodies used as treatments for aspects of metabolic disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cambridge Science Week 2017</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2418063A-7C92-432E-ACBB-E8CC3D48C5EF</gtr:id><gtr:impact>took part in Cambridge Science week and put on a display on personalised medicine and health using advanced biochemical techniques.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Week cambridge 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>66C7732D-53B2-4566-A589-E196BBB2759C</gtr:id><gtr:impact>: volunteering on 13th March 2016 Cambridge science festival HNR stand: Blood, Fat &amp;amp; the Future</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>2nd Metabolomics Sardinian Scientific School</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A28A19EC-09C1-401C-AC7E-A2C2BA40B67A</gtr:id><gtr:impact>2nd Metabolomics Sardinian Scientific School was aimed at post-grad students new to the field of metabolomics. We gave seminars and workshops in various tools and techniques in metabolomics.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Work experience for two school boys</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>56CAF078-6331-4007-ABB3-3AB9E0D98FF7</gtr:id><gtr:impact>Work experience for two school boys: two school boys spent a week in my lab following members around to get some experience of what its like being a scientist.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Intermediate fellowship for KT</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>5C4DA1FA-0BEF-424E-800B-39A06B5932C9</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Astra Zeneca CASE studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>AD06E715-3FB3-4B63-86C0-498A893B10FD</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>417000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GSK-Astra Zeneca partnership awards</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>F466F79D-BEE8-4CED-9E7F-00CACA2B3BDC</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MedImmune Cambridge</gtr:department><gtr:description>Medimmune industrial studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>MedImmune</gtr:fundingOrg><gtr:id>6B6D94C1-EC1E-4E4D-A684-AAE81D3FF1FE</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>124000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Technology Development Grant, MetaboFlow - the development of standardised workflows for processing metabolomics data to aid reproducible data sharing and big data initiatives</gtr:description><gtr:end>2019-11-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>202952/B/16/Z</gtr:fundingRef><gtr:id>14FD5CAA-68C1-4E70-9BA1-4FDA8B9A03E3</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>SACN advisory committee on dietary fats</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>82B700E4-D763-4B38-B168-CF881D1488CC</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/918D310B-2545-4827-9D75-F428EDBE7260"><gtr:id>918D310B-2545-4827-9D75-F428EDBE7260</gtr:id><gtr:title>Short-term benefits of an unrestricted-calorie traditional Mediterranean diet, modified with a reduced consumption of carbohydrates at evening, in overweight-obese patients.</gtr:title><gtr:parentPublicationTitle>International journal of food sciences and nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/de4edba587b5a18635cfa6c3585275cb"><gtr:id>de4edba587b5a18635cfa6c3585275cb</gtr:id><gtr:otherNames>Salvia R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0963-7486</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4AF5324F-F4FD-4621-84CF-31E6B7C7BD2E"><gtr:id>4AF5324F-F4FD-4621-84CF-31E6B7C7BD2E</gtr:id><gtr:title>Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/590c8a9618b273cc7c1e0848dd49db27"><gtr:id>590c8a9618b273cc7c1e0848dd49db27</gtr:id><gtr:otherNames>Lotta LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ACCA1FDB-908B-4121-A80E-05C355A576D6"><gtr:id>ACCA1FDB-908B-4121-A80E-05C355A576D6</gtr:id><gtr:title>Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3d6d2388cc5de7578f7aeba3e818c521"><gtr:id>3d6d2388cc5de7578f7aeba3e818c521</gtr:id><gtr:otherNames>Taegtmeyer H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/38A84A6F-F5A0-42C4-9A60-3A6040685C4E"><gtr:id>38A84A6F-F5A0-42C4-9A60-3A6040685C4E</gtr:id><gtr:title>Novel ketone diet enhances physical and cognitive performance.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ac60c126dd05fe5ce69dfda4816f4de9"><gtr:id>ac60c126dd05fe5ce69dfda4816f4de9</gtr:id><gtr:otherNames>Murray AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B9F660D5-AC35-4844-A05A-188216380998"><gtr:id>B9F660D5-AC35-4844-A05A-188216380998</gtr:id><gtr:title>Association of Plasma Phospholipid n-3 and n-6 Polyunsaturated Fatty Acids with Type 2 Diabetes: The EPIC-InterAct Case-Cohort Study.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5d49fb8098ab21616c9235687213475f"><gtr:id>5d49fb8098ab21616c9235687213475f</gtr:id><gtr:otherNames>Forouhi NG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/680941EE-9516-422A-A6BB-735D82905EE1"><gtr:id>680941EE-9516-422A-A6BB-735D82905EE1</gtr:id><gtr:title>Response to Comment on Lee et al. Diabetes 2015;64:2836-2846. Comment on Roberts et al. Diabetes 2015;64:471-484.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/59b6e3728c2503ea027017abe00a44c7"><gtr:id>59b6e3728c2503ea027017abe00a44c7</gtr:id><gtr:otherNames>Roberts LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BCADD3E9-6AEA-43EC-997F-64E4F638F2D2"><gtr:id>BCADD3E9-6AEA-43EC-997F-64E4F638F2D2</gtr:id><gtr:title>The translation of lipid profiles to nutritional biomarkers in the study of infant metabolism.</gtr:title><gtr:parentPublicationTitle>Metabolomics : Official journal of the Metabolomic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5a4c5bb2295df1ba4ff1ccbe4d58a364"><gtr:id>5a4c5bb2295df1ba4ff1ccbe4d58a364</gtr:id><gtr:otherNames>Acharjee A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1573-3882</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AF63EA75-92D4-4ECB-8C81-5A6EADF52561"><gtr:id>AF63EA75-92D4-4ECB-8C81-5A6EADF52561</gtr:id><gtr:title>MetaboLights: An Open-Access Database Repository for Metabolomics Data.</gtr:title><gtr:parentPublicationTitle>Current protocols in bioinformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1c57afb01c107304176a8da6715507ec"><gtr:id>1c57afb01c107304176a8da6715507ec</gtr:id><gtr:otherNames>Kale NS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1934-3396</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/89C9E539-38DE-4D43-90B5-1EFE81F605A8"><gtr:id>89C9E539-38DE-4D43-90B5-1EFE81F605A8</gtr:id><gtr:title>Nutritional Ketosis Alters Fuel Preference and Thereby Endurance Performance in Athletes.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/67be2475aac9535fc2f1fb52d61463db"><gtr:id>67be2475aac9535fc2f1fb52d61463db</gtr:id><gtr:otherNames>Cox PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2EB91B84-EFE6-4C9A-BA20-B217F94A93CE"><gtr:id>2EB91B84-EFE6-4C9A-BA20-B217F94A93CE</gtr:id><gtr:title>Genes and miRNA expression signatures in peripheral blood mononuclear cells in healthy subjects and patients with metabolic syndrome after acute intake of extra virgin olive oil.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/00b43d909c5d39d98458ec4bba40bf04"><gtr:id>00b43d909c5d39d98458ec4bba40bf04</gtr:id><gtr:otherNames>D'Amore S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9A86F5BB-6068-4E1F-8156-1ADDC9E229C7"><gtr:id>9A86F5BB-6068-4E1F-8156-1ADDC9E229C7</gtr:id><gtr:title>Erratum: Adipose tissue fatty acid chain length and mono-unsaturation increases with obesity and insulin resistance.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5b0fe1561e92f157420919eb81c6a910"><gtr:id>5b0fe1561e92f157420919eb81c6a910</gtr:id><gtr:otherNames>Tan CY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/472A1324-FB7F-4673-AB23-7C516DCCA511"><gtr:id>472A1324-FB7F-4673-AB23-7C516DCCA511</gtr:id><gtr:title>Statistical Health Monitoring Applied to a Metabolomic Study of Experimental Hepatocarcinogenesis: An Alternative Approach to Supervised Methods for the Identification of False Positives.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0f38801c583abf138dba148152d5d8dc"><gtr:id>0f38801c583abf138dba148152d5d8dc</gtr:id><gtr:otherNames>Del Carratore F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A706A600-553A-4D1F-B59A-190F7A100514"><gtr:id>A706A600-553A-4D1F-B59A-190F7A100514</gtr:id><gtr:title>Metabolomics dataset of PPAR-pan treated rat liver.</gtr:title><gtr:parentPublicationTitle>Data in brief</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/605afa4d43c7798be6ab908c49549eb0"><gtr:id>605afa4d43c7798be6ab908c49549eb0</gtr:id><gtr:otherNames>Ament Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2352-3409</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E9E12F7D-A803-4E87-8AE2-B85E0AAE4A91"><gtr:id>E9E12F7D-A803-4E87-8AE2-B85E0AAE4A91</gtr:id><gtr:title>Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8face52ad7d0211d931dd00159b1afe3"><gtr:id>8face52ad7d0211d931dd00159b1afe3</gtr:id><gtr:otherNames>Hall Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CFDB4DA3-2546-4213-8DA5-B6B4F99A9B9C"><gtr:id>CFDB4DA3-2546-4213-8DA5-B6B4F99A9B9C</gtr:id><gtr:title>Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/567a6df44fe9ec1809d4232be794446a"><gtr:id>567a6df44fe9ec1809d4232be794446a</gtr:id><gtr:otherNames>Yang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9DD7420C-F2BB-4AD4-8656-B7AC7C8E957B"><gtr:id>9DD7420C-F2BB-4AD4-8656-B7AC7C8E957B</gtr:id><gtr:title>Integration of metabolomics, lipidomics and clinical data using a machine learning method.</gtr:title><gtr:parentPublicationTitle>BMC bioinformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5a4c5bb2295df1ba4ff1ccbe4d58a364"><gtr:id>5a4c5bb2295df1ba4ff1ccbe4d58a364</gtr:id><gtr:otherNames>Acharjee A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2105</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/15AF1348-2912-49A1-A395-31B8B84A4D95"><gtr:id>15AF1348-2912-49A1-A395-31B8B84A4D95</gtr:id><gtr:title>Myc Expression Drives Aberrant Lipid Metabolism in Lung Cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8face52ad7d0211d931dd00159b1afe3"><gtr:id>8face52ad7d0211d931dd00159b1afe3</gtr:id><gtr:otherNames>Hall Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/99E22FC6-A761-497B-AA0F-BFD6F98FEED0"><gtr:id>99E22FC6-A761-497B-AA0F-BFD6F98FEED0</gtr:id><gtr:title>C13orf31 (FAMIN) is a central regulator of immunometabolic function.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/32711005bbbc3c895889b86f934b0688"><gtr:id>32711005bbbc3c895889b86f934b0688</gtr:id><gtr:otherNames>Cader MZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9298D56A-C6D3-4F12-85D1-844B0318220F"><gtr:id>9298D56A-C6D3-4F12-85D1-844B0318220F</gtr:id><gtr:title>Computational tools and workflows in metabolomics: An international survey highlights the opportunity for harmonisation through Galaxy.</gtr:title><gtr:parentPublicationTitle>Metabolomics : Official journal of the Metabolomic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/47b13b4b53a93ef0beae5af646542462"><gtr:id>47b13b4b53a93ef0beae5af646542462</gtr:id><gtr:otherNames>Weber RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1573-3882</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BEB2E759-BE13-4237-8AB3-847DEC2D7A2E"><gtr:id>BEB2E759-BE13-4237-8AB3-847DEC2D7A2E</gtr:id><gtr:title>Inorganic Nitrate Mimics Exercise-Stimulated Muscular Fiber-Type Switching and Myokine and ?-Aminobutyric Acid Release.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/59b6e3728c2503ea027017abe00a44c7"><gtr:id>59b6e3728c2503ea027017abe00a44c7</gtr:id><gtr:otherNames>Roberts LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5A939906-DF7C-4676-B4B2-81FCAEA82CAF"><gtr:id>5A939906-DF7C-4676-B4B2-81FCAEA82CAF</gtr:id><gtr:title>Blood triacylglycerols: a lipidomic window on diet and disease.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d0e3ad7533d1f938a8e188b5620f00a"><gtr:id>4d0e3ad7533d1f938a8e188b5620f00a</gtr:id><gtr:otherNames>Sanders F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/78FAB317-551F-4F08-99D1-5224A1C7F4EF"><gtr:id>78FAB317-551F-4F08-99D1-5224A1C7F4EF</gtr:id><gtr:title>A targeted metabolomics assay for cardiac metabolism and demonstration using a mouse model of dilated cardiomyopathy.</gtr:title><gtr:parentPublicationTitle>Metabolomics : Official journal of the Metabolomic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/60c46c8b27756d4e59f65028a7eb54f2"><gtr:id>60c46c8b27756d4e59f65028a7eb54f2</gtr:id><gtr:otherNames>West JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1573-3882</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AEF7E897-2D08-4C2E-8A58-B67648D0EBA3"><gtr:id>AEF7E897-2D08-4C2E-8A58-B67648D0EBA3</gtr:id><gtr:title>Interlaboratory Reproducibility of a Targeted Metabolomics Platform for Analysis of Human Serum and Plasma.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/349eb91011e40528bfc06aa005b52db2"><gtr:id>349eb91011e40528bfc06aa005b52db2</gtr:id><gtr:otherNames>Siskos AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2A1AF94E-E004-499F-935F-6A8A8014883F"><gtr:id>2A1AF94E-E004-499F-935F-6A8A8014883F</gtr:id><gtr:title>IsotopicLabelling: an R package for the analysis of MS isotopic patterns of labelled analytes.</gtr:title><gtr:parentPublicationTitle>Bioinformatics (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f458f52928a4d2c86d97921db4840720"><gtr:id>f458f52928a4d2c86d97921db4840720</gtr:id><gtr:otherNames>Ferrazza R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1367-4803</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/P011705/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>